Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial

BACKGROUND: SGTL2-inhibitors are a cornerstone in the treatment of heart failure, but data on patients with acute myocardial infarction (AMI) is limited. The EMMY trial was the first to show a significant reduction in NTproBNP levels as well as improved cardiac structure and function in post-AMI pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedikt, Martin, Mangge, Harald, Aziz, Faisal, Curcic, Pero, Pailer, Sabine, Herrmann, Markus, Kolesnik, Ewald, Tripolt, Norbert J., Pferschy, Peter N., Wallner, Markus, Zirlik, Andreas, Sourij, Harald, von Lewinski, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324245/
https://www.ncbi.nlm.nih.gov/pubmed/37407956
http://dx.doi.org/10.1186/s12933-023-01904-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324245/
https://www.ncbi.nlm.nih.gov/pubmed/37407956
http://dx.doi.org/10.1186/s12933-023-01904-6

Ejemplares similares